UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): June 28, 2023
Trevi Therapeutics, Inc.
(Exact Name of Registrant as Specified in Charter)
| | | | |
Delaware |
| 001-38886 |
| 45-0834299 |
(State or Other Jurisdiction of Incorporation) |
| (Commission File Number) |
| (IRS Employer Identification No.) |
| | |
195 Church Street, 16th Floor New Haven, Connecticut |
| 06510 |
(Address of Principal Executive Offices) |
| (Zip Code) |
Registrant’s telephone number, including area code: (203) 304-2499
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| |
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| | | | |
Title of each class |
| Trading symbol(s) |
| Name of each exchange on which registered |
Common stock, $0.001 par value per share |
| TRVI |
| The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
On June 28, 2023, Trevi Therapeutics, Inc., a Delaware corporation (the “Company”) held its 2023 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders approved an amendment (the “Amendment”) to the Company’s restated certificate of incorporation (“Certificate of Incorporation”) to update the existing director exculpation provision to include certain of the Company’s senior corporate officers.
The Amendment became effective upon the Company’s filing of a Certificate of Amendment to the Restated Certificate of Incorporation with the Secretary of State of the State of Delaware on June 28, 2023 (the “Certificate of Amendment”).
The foregoing description of the terms of the Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Certificate of Amendment, a copy of which is attached as Exhibit 3.1 hereto and is incorporated by reference herein.
Item 5.07 Submission of Matters to a Vote of Security Holders
At the Annual Meeting, the Company’s stockholders voted on the following proposals:
1. The following nominees were elected to the Board of Directors of the Company as Class I directors for terms expiring at the 2026 annual meeting of stockholders.
| | | | | | | | | | | | |
| | For | | | Withheld | | | Broker Non-Votes | |
James Cassella, Ph.D. | | | 31,870,641 | | | | 5,581,669 | | | | 7,125,050 | |
Michael Heffernan | | | 37,302,433 | | | | 149,877 | | | | 7,125,050 | |
2. The Certificate of Amendment was approved.
| | | | |
For: | | | 37,404,705 | |
Against: | | | 35,316 | |
Abstain: | | | 12,289 | |
Broker Non-Votes: | | | 7,125,050 | |
3. The appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2023 was ratified.
| | | | |
For: | | | 44,552,048 | |
Against: | | | 8,732 | |
Abstain: | | | 16,580 | |
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | |
| | TREVI THERAPEUTICS, INC. |
| | |
Date: June 28, 2023 | | By: | /s/ Lisa Delfini |
| | | Name: Lisa Delfini |
| | | Title: Chief Financial Officer |
